SBIR/STTR Research Award
SBIR Phase I: Developing a Rapid Antibody Generation Platform for Emerging COVID-19 Variants
Award amount
$256,000Program and phase
SBIR · Phase IAward year
2020Award details
- Awarding agency
- National Science Foundation
- Branch
- Not reported
- Recipient company
- A-ALPHA BIO INC
- Proposal award date
- 2020-09-01
- Contract end date
- 2021-08-31
- UEI
- HCTNBH41FKL1
- Solicitation number
- Not reported
- Topic code
- BT
Research abstract
The broader impact of this Small Business Innovation Research (SBIR) Phase I project is to improve and accelerate the development of antibody therapies to fight the COVID-19 pandemic. Antibody therapies are in development to target SARS-CoV-2, the virus r
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- SBIR Phase II: Developing a Platform for Multiplexed Drug Profiling Using Yeast Synthetic Agglutination
- SBIR Phase I: Developing a Platform for Multiplexed Drug Profiling Using Yeast Synthetic Agglutination
Research funding history
3 SBIR/STTR records share this UEI (2018–2020). Reported award amounts total $1,101,472. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: National Science Foundation